Ninčević, Vjera <br/><br/>
Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.  [electronic resource] 

 -  International journal of molecular sciences  Nov 2019 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1422-0067 
<br/><br/><label>Standard No.: </label>10.3390/ijms20235831  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Diabetic Nephropathies--drug therapy<br/>Drug Synergism<br/>Glucagon-Like Peptide-1 Receptor--metabolism<br/>Humans<br/>Hypoglycemic Agents--pharmacology<br/>Kidney--drug effects<br/>Sodium-Glucose Transporter 2--metabolism<br/>Sodium-Glucose Transporter 2 Inhibitors--pharmacology<br/>Glucagon-Like Peptide-1 Receptor Agonists